1199809-26-1

Basic information

• Product Name: 6-Chloro-9-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-Methyl-b-D-erythro-pentofuranosyl]-9H-purin-2-aMine
• Synonyms: 6-Chloro-9-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-Methyl-b-D-erythro-pentofuranosyl]-9H-purin-2-aMine;6-Chloro-9-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-methyl-beta-D-erythro-pentofuranosyl]-9H-purin-2-amine;(2R,3R,4R,5R)-5-(2-amino-6-chloro-9H-purin-9-yl)-2-((benzoyloxy)methyl)-4-fluoro-4-methyltetrahydrofuran-3-yl benzoate
• CAS NO: 1199809-26-1
• Molecular Formula: C₂₅H₂₁ClFN₅O₅
• Molecular Weight: 525.9161432
• Mol File: 1199809-26-1.mol
• Article Data: 16

Chemical Properties

• Melting Point: 160-162℃
• Appearance: /
• Density: 1.52
• CAS DataBase Reference: 6-Chloro-9-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-Methyl-b-D-erythro-pentofuranosyl]-9H-purin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-9-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-Methyl-b-D-erythro-pentofuranosyl]-9H-purin-2-aMine(1199809-26-1)
• EPA Substance Registry System: 6-Chloro-9-[(2R)-3,5-di-O-benzoyl-2-deoxy-2-fluoro-2-Methyl-b-D-erythro-pentofuranosyl]-9H-purin-2-aMine(1199809-26-1)

Safety Data

• Hazardous Substances Data: 1199809-26-1(Hazardous Substances Data)

Usage

Structure

Purine base with a 6-chloro substitution and a 2-deoxy-2-fluoro-2-methyl-b-D-erythro-pentofuranosyl group

Functional Groups

Two benzoyl groups attached to the 3 and 5 positions of the sugar moiety

Potential Pharmaceutical Applications

Structural similarity to nucleosides, important in DNA and RNA synthesis

Reactivity

Presence of fluoro and chloro group introduces potential reactivity

Pharmacological Properties

Possibility for exploration for therapeutic purposes

Upstream product

• 1199809-24-9 (((2R,3R,4R,5R)-3-(benzoyloxy)-5-bromo-4-fluoro-4-methyltetrahydrofuran-2-yl)methyl benzoate) 
• 10310-21-1 2-amino-6-chloropurine 
• 10310-21-1 2-Amino-6-chloropurin 
• 874638-80-9 ((2R,3R,4R)-3-benzoyloxy-4-fluoro-4-methyl-5-oxo-tetrahydrofuran-2-yl)methyl benzoate 
• 1199809-22-7 ((2R,3R,4R,5R)-3-(benzoyloxy)-4-fluoro-5-hydroxy-4-methyltetrahydrofuran-2-yl)methyl benzoate 
• 130606-67-6 C₁₁H₁₈O₄ 
• 93635-76-8 (2S,3R)-3-[(4R)-2,2-dimethyl-[1,3]dioxolane-4-yl]-2,3-dihydroxy-2-methylpropionic acid ethyl ester 
• 879551-01-6 (4S,5R)-ethyl-5-((R)-2,2-dimethyl-1,3-dioxolan-4-yl)-4-meth-yl-1,3,2-dioxathiolane-4-carboxylate 2,2-dioxide 
• 879551-04-9 (3R,4R,5R)-3?fluoro?4?hydroxy?5?(hydroxymethyl)?3?methyltetrahydrofuran?2?one 
• 1033394-83-0 C₁₁H₁₉FO₅ 

Downstream Products

• 1199809-27-2 (2R,3R,4R,5R)-5-(2-amino-6-methoxy-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol 
• 1199809-29-4 (2R,3R,4R,5R)-5-(2-amino-6-(benzyloxy)-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol 
• 1199809-30-7 (2R,3R,4R,5R)-5-(2-amino-6-ethoxy-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol 
• 1261253-99-9 C₂₆H₃₅FN₇O₇P 
• 1261253-82-0 C₂₂H₂₈FN₆O₈P 
• 1261254-01-6 C₂₃H₃₀FN₆O₈P 
• 1231747-11-7 (2S)cyclopentyl 2-((((2R,3R,4R,5R) 5-(2-amino-6-hydroxy-9H-purin9yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate 
• 1064685-09-1 (2S)methyl 2-((((2R,3R,4R,5R) 5(2-amino-6-(azetidin-1-yl)-9H-purin-9-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate 
• 1261253-96-6 C₂₅H₃₃FN₇O₇P 
• 1261254-15-2 C₂₆H₃₅FN₇O₇P 
• 1261254-17-4 C₂₄H₃₁FN₇O₇P 
• 1261253-98-8 C₂₅H₃₃FN₇O₇P 
• 1261254-18-5 C₂₆H₃₅FN₇O₇P 
• 1261254-00-5 C₂₇H₃₇FN₇O₇P 

Relevant articles and documents

BI- AND MONOCYCLIC NUCLEOSIDE ANALOGS FOR TREATMENT OF HEPATITIS E

The present disclosure is directed toward bi- and monocyclic nucleoside analogs, and compositions comprising these compounds for use in the treatment of hepatitis E infections.

BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION

Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX and Formula X that are highly active against the HCV virus when administered in an effective amount to a host in need thereof. The ho

Beta-D-2'-DEOXY-2'-alpha-FLUORO-2'-beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT

A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.